June 22, 2011 -- Source BioScience (LSE: SBS), the international diagnostics and genetic analysis business, announces the launch of the largest publicly available clone and antibody resource portfolio for research purposes in the world in conjunction with an innovative, intelligent search engine to provide ready access for researchers.
Researchers will be able to access over 20 million clones, representing nearly every known human gene and most other organisms important in biological research. In addition, there is a portfolio of over 90,000 antibodies for applications in both research and diagnostics.
Clones and antibodies are used as primary research tools across a broad spectrum of biological sciences. Currently, Source BioScience supplies research resources, screening and diagnostic services to the life sciences industry in over 90 countries worldwide.
Super fast access and intuitive searching of the vast portfolio will be possible with the new Source BioScience GenomeCube® search engine. GenomeCube® is an intelligent web-based portal which can search the entire Source BioScience clone and antibody portfolio using an array of search terms and common identifiers used in international scientific databases.
Dr Nick Leaves, COO at Source BioScience, commented: “The Source BioScience clone and antibody resource represents an invaluable tool for biological research. Researchers will now be able to locate and buy these products from a single site. In addition, with the launch of our enhanced search engine, GenomeCube®, researchers will be able to access this library with comprehensive annotation, and scientific and technical support in a fraction of the time. We believe this one-stop shop will make a significant difference to researchers.”
As an indication of the utility and power of the new search engine, more than 10 million links have been established from international scientific databases to GenomeCube® to enable scientists access to the most current and detailed information to support their research.
Dr Nick Ash, CEO of Source BioScience, added: “The breadth and depth of this research resource has been significantly enhanced as a result of Source BioScience acquiring Berlin-based imaGenes in 2010. In the six months since the acquisition we have fully integrated the business activities and have combined both companies’ clone and antibody portfolios. Over £1 million has been invested in GenomeCube® to create a single, intelligent portal to enable ready access to the entire portfolio. The launch of this service marks a significant milestone for the Company.”
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO
Tel: +44 (0) 115 973 9010
Email: enquiries@sourcebioscience.com
www.sourcebioscience.com
College Hill (PR Agency to Source BioScience)
Melanie Toyne Sewell/ Dimithri Wignarajah
Tel: +44 (0)207 457 2020
Email: sourcebioscience@collegehill.com
About Source BioScience:
Source BioScience plc (LSE: SBS) is an international diagnostics and genetic analysis business serving the healthcare and research markets. Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. The PharmaBiotech division offers support for early stage therapeutic development, offering a ‘one-stop shop’ from tissue pathology, immunohistochemistry, sophisticated image analysis, biomarker determination and assay development to pharmacogenomics including genotyping and gene expression analysis. The Group has its headquarters in Nottingham, UK. Further information about Source BioScience can be found at www.sourcebioscience.com
